Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion, as the ...

Merck, Black Hills, and Virtus Investment Partners are good choices for investors seeking reliable passive income. Their ...

Merck's first-quarter net income increased as ... Sales of animal-health products, a category that has risen in significance in recent years alongside the number of pets in Americans' lives ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

In today's Pharmalittle roundup, we're reading about Roche and Merck struggles with tariffs, NEJM quizzed by U.S. attorney, ...

Merck said it still expects 2025 total sales ... We sell different types of products and services to both investment professionals and individual investors. These products and services are usually ...